牛皮癣药物市场－全球产业规模、份额、趋势、机会及预测，依治疗类型、作用机制、给药途径、地区及竞争情况细分，2020-2030 年预测

2024 年全球干癣药物市场规模达 210.6 亿美元，预计到 2030 年将以 6.57% 的复合年增长率成长，在预测期末达到可观的市场规模。受全球银屑病发病率上升、治疗手段不断进步以及对更有效和个性化治疗的需求不断增长的推动，该市场正在快速发展。干癣是一种慢性自体免疫疾病，会导致皮肤发红、发炎和鳞状病变，影响全球数百万人，并严重影响生活品质。随着认知度和诊断能力的提高，干癣的识别和治疗正变得越来越普遍。银屑病的治疗方法多种多样，涵盖外用药物、光疗、全身用药和生物疗法。尤其是生物製剂，它透过提供更高的疗效和安全性，彻底改变了治疗模式。随着研究的不断深入、医疗政策的支持以及患者对标靶治疗需求的不断增长，银屑病药物市场在全球范围内持续增长。

关键市场驱动因素

牛皮癣盛行率不断上升

主要市场挑战

对牛皮癣病因和诱因的了解有限

主要市场趋势

生物疗法占主导地位

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球牛皮癣药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗类型（生物药物、小分子系统药物、热带疗法）
  • 依作用机制分类（TNF α 抑制剂、PDE4 抑制剂、白血球介素抑制剂等）
  • 依给药途径（口服、肠胃外、外用）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美银屑病药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲牛皮癣药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区干癣药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美牛皮癣药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲牛皮癣药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球牛皮癣药物市场：SWOT 分析

第 14 章：竞争格局

• Glanbia Plc
• Pfizer Inc.
• Bayer AG
• Amway Corp.
• GlaxoSmithKline plc.
• Good Health New Zealand
• The Nature's Bounty Co.
• NOW Foods
• Abbott
• Herbalife Nutrition

第 15 章：策略建议

第16章调查会社について・免责事项

Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.

Key Market Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches

A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.

Key Market Players

• Glanbia Plc
• Pfizer Inc.
• Bayer AG
• Amway Corp.
• GlaxoSmithKline plc.
• Good Health New Zealand
• The Nature's Bounty Co.
• NOW Foods
• Abbott
• Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Others

Psoriasis Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Topical

Psoriasis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Route of Administrations
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
  • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Treatment
  • 6.2.2. By Mechanism of Action
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psoriasis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Treatment
      • 6.3.1.2.2. By Mechanism of Action
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Psoriasis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Treatment
      • 6.3.2.2.2. By Mechanism of Action
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Psoriasis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Treatment
      • 6.3.3.2.2. By Mechanism of Action
      • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Treatment
  • 7.2.2. By Mechanism of Action
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psoriasis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Treatment
      • 7.3.1.2.2. By Mechanism of Action
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Treatment
      • 7.3.2.2.2. By Mechanism of Action
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. Italy Psoriasis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type of Treatment
      • 7.3.3.2.2. By Mechanism of Action
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. France Psoriasis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Treatment
      • 7.3.4.2.2. By Mechanism of Action
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Psoriasis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Treatment
      • 7.3.5.2.2. By Mechanism of Action
      • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Treatment
  • 8.2.2. By Mechanism of Action
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Psoriasis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Treatment
      • 8.3.1.2.2. By Mechanism of Action
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Psoriasis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Treatment
      • 8.3.2.2.2. By Mechanism of Action
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Psoriasis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Treatment
      • 8.3.3.2.2. By Mechanism of Action
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Psoriasis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Treatment
      • 8.3.4.2.2. By Mechanism of Action
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Psoriasis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Treatment
      • 8.3.5.2.2. By Mechanism of Action
      • 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Treatment
  • 9.2.2. By Mechanism of Action
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Psoriasis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Treatment
      • 9.3.1.2.2. By Mechanism of Action
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. Argentina Psoriasis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Treatment
      • 9.3.2.2.2. By Mechanism of Action
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. Colombia Psoriasis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Treatment
      • 9.3.3.2.2. By Mechanism of Action
      • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Treatment
  • 10.2.2. By Mechanism of Action
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Psoriasis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Treatment
      • 10.3.1.2.2. By Mechanism of Action
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Treatment
      • 10.3.2.2.2. By Mechanism of Action
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. UAE Psoriasis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Treatment
      • 10.3.3.2.2. By Mechanism of Action
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Glanbia Plc
  • 14.1.1. Business Overview
  • 14.1.2. Mechanism of Action Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Bayer AG
• 14.4. Amway Corp.
• 14.5. GlaxoSmithKline plc.
• 14.6. Good Health New Zealand
• 14.7. The Nature's Bounty Co.
• 14.8. NOW Foods
• 14.9. Abbott
• 14.10. Herbalife Nutrition

15. Strategic Recommendations

16. About Us & Disclaimer